Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Publication Title
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Document Type
Article
Publication Date
2-1-2025
Keywords
washington; swedish; swedish cancer
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
DOI
10.1038/s41375-024-02487-1
